Glypican-5, a novel cancer target
ICR collaboration and licensing opportunity.
Principal Scientists: Dr Janet Shipley
GPC5 has been identified as a potential therapeutic target in soft tissue sarcoma, breast carcinoma, lung carcinoma, lymphoma, medulloblastoma and glioblastoma. This target is amenable to antibody mediated therapies. It also has potential as a biomarker.
For further information contact Jonathan Beech or download the PDF flyer.